Skip to Main Content

Paper Details

Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Clin Cardiol
1
2022
ASCVD, CKD, Cholesterol, Chronic kidney disease, Dyslipidemia, LDL-, Low-Density Lipoprotein Cholesterol, PCSK9i, Statin, atherosclerotic cardiovascular disease, cholesterol, chronic kidney disease, dyslipidemia, ezetimibe, lipoprotein cholesterol, low-density lipoprotein cholesterol, patients, proprotein convertase, statin, subtilisin/kexin
Author NameAffiliation
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Mikhail KosiborodThe George Institute for Global Health, University of New South Wales
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School
Christopher P CannonBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School
Christopher P CannonBaim Institute for Clinical Research
Christie M BallantyneBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
  • 1 - 7

Datasets

Release 1.2